Floatz logo

Fpv-Cv301

Small Bowel Cancers

National Cancer Institute (NCI)vaccinePhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Small Bowel Cancers cohort.

Asset / SponsorPhaseRating
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP
National Cancer Institute (NCI)
Phase 2CCC
n-803
National Cancer Institute (NCI)
Phase 2CC
Immunocytokine Nhs-Il12
National Cancer Institute (NCI)
Phase 2CC

Same molecule, other indications

Fpv-Cv301 is also rated in:

colorectal cancerDormant
CCC
Indicative ·
50 / 100
View asset →
Prostate CancerDormant
CC
Indicative ·
45 / 100
View asset →
Metastatic CancerDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →